crizotinib

The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.

The study combined large-scale protein post-translational modification datasets with protein-protein interaction data to profile cell signaling in lung cancer.

The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.